Pharmaceuticals

Novo Nordisk Stock (NVO): Cuts Forecast

Novo Nordisk shows strong growth in obesity care but faces rising risks and competitive pressures as it heads into 2026.

Hims & Hers Stock Hit Hard—Can Global Growth Save It?

After a 35% stock drop from a Novo Nordisk fallout, Hims & Hers is betting big on global expansion. But will regulators let it bounce back?

Pfizer Files Second Lawsuit Against Novo Nordisk for Metsera

AbbVie Beats Q3 EPS Estimates with $1.86 Results

Thermo Fisher Nears ~$10 B All-Cash Acquisition of Clario, Sources Say

Rockwell Medical to Showcase Hemodialysis Solutions at ASN 2025

Rockwell Medical will exhibit at ASN Kidney Week 2025, showcasing its hemodialysis product portfolio from November 6-9 in Houston.

Novartis Q3 Net Profit Rises 23% on Strong Drug Sales

Novartis posted a 23% profit rise as Kisqali, Kesimpta, and Pluvicto drove sales gains, offsetting U.S. generic pressure. Guidance reaffirmed.

Trump's Drug-Price Talk Jolts Eli Lilly—Shares Slide on Drug-Pricing Concerns

Eli Lilly shares slid after Trump renewed vows to cut diabetes drug prices, extending losses in pre-market trading as investors weighed political risk against strong GLP-1 fundamentals.

Telomir Pharma Stock Soars 35% on Epigenetic Therapy Breakthrough

Telomir Pharmaceuticals surged after new data showed its lead drug could reset disease drivers, sparking investor buzz in a high-risk biotech play.

Medtronic Board Changes and EPS Guidance Update

Medtronic raised its 2026 profit forecast as strong demand offsets tariff risks. See what this means for investors in healthcare device stocks.

Indivior Stock (INDV): Strong Earnings Boost Investor Confidence

Indivior exceeded Q2 2025 expectations, raising full-year forecasts, driven by strong Sublocade demand, boosting stock by ~21%.

CVS Health Stock (CVS): Strong Q2 Performance and Future Outlook

CVS Health showed strong Q2 2025 results, boosting EPS guidance and share price, driven by Aetna and pharmacy growth.

Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth

Biogen's Q2 2025 shows strong growth with new drugs boosting revenue and EPS, despite challenges in legacy MS treatments.

Exact Sciences Stock (EXAS): Cologuard Plus Expansion Benefits

Exact Sciences broadens partnership with Humana, offering Cologuard Plus for 5.8 million members, enhancing access and driving growth.

ProKidney Stock (PROK): Is the Hype Justified?

ProKidney's stock soared after promising Phase 2 trial results, highlighting the potential but also the risks in biotech investments.